Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis

Abstract: Atypical hemolytic uremic syndrome (aHUS), a life-threatening complement-mediated disorder, is now treatable with terminal complement inhibitors like eculizumab. Although effective, these therapies are costly, and increase susceptibility to infections, notably meningococcal disease, raisin...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Amy Hockman, Sydney Anuskiewicz, Emily Brennan, Saifur R. Chowdhury, Alexander Coltoff, Jacqueline N. Poston, Charles Greenberg, Benjamin Djulbegovic
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-12-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2473952925004793
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!